February 5th 2025
Of the 118 biologics losing exclusivity over the next decade, only 10% have biosimilars in development, meaning a vast majority of biologics have no pipeline, which limits savings potential for the health care system.
January 31st 2025
Stakeholders Joust Over Biosimilar Availability at PCOC20
September 25th 2020A diverse panel from practice, payer, and wholesale perspectives convened at The American Journal of Managed Care®'s Patient-Centered Oncology Care® 2020 virtual conference to hash out one of the hottest issues in biosimilar availability right now.
Vizient Looks to Biosimilars To Temper COVID-19 Price Inflation
July 31st 2020Vizient predicts that drug price inflation, partly due to the coronavirus disease 2019 (COVID-19), will be 3.29% in 2021 and is banking on biosimilars to help contain the rising cost of medication, it said in a comprehensive review for its member health companies.
NeuClone Completes Early Testing for Psoriasis Biosimilar
April 8th 2020NeuClone said phase 1 patient monitoring and blood sampling has been completed for its ustekinumab biosimilar candidate, which is targeted at the $6.6 billion in annual revenue earned by Stelara, a Janssen Pharmaceutical Companies product.
Study: Adalimumab Plus Hydroxychloroquine Leads to Hair Regrowth in Lichen Planopilaris
February 27th 2020Lichen planopilaris (LPP) is a type of scarring hair loss that occurs when lichen plaus, a relatively common inflammatory skin disease, affects areas of skin where hair grows. It destroys the hair follicle and replaces it with scarring, resulting in permanent hair loss. LPP’s causes and pathology are unknown.
2019 Saw Mounting Evidence to Support Nonmedical Switching, Review Article Says
February 21st 2020A recent year-in-review article outlines studies published in 2019 about nonmedical switching from originator biologics to biosimilars in rheumatoid arthritis, psoriatic arthritis, and axial spondyloarthritis.
AbbVie: Next-Generation Skyrizi and Rinvoq Are Showing Traction in Humira Space
February 21st 2020Pharmaceutical giant AbbVie reports strong revenues for next-generation products the company hopes will provide fill-in revenue as Humira (adalimumab) sales decline and more biosimilars to the blockbuster arthritis drug enter the market.
No Higher Risk of Cancer for Patients With Psoriasis Treated With Biologics, Analysis Finds
February 19th 2020The review found no increased risk of cancer when looking at both keratinocyte cancer and lymphomas in patients on biologics vs conventional therapy. Overall, however, patients with psoriasis appear to have a slightly increased risk of certain cancers.